



## ASH 2022 abstracts: What's hot in MDS?

To help navigate the exciting content being presented at the 64th ASH Annual Meeting & Exposition, the MDS Hub Steering Committee members have provided their recommendations for the top abstracts to look out for in MDS.



**Click**  
the abstracts  
to view



**Scientific Education Support**

## Treatment patterns

<b>220</b>	<a href="#"><u>A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results</u></a>
<b>389</b>	<a href="#"><u>Real-World Outcomes of Patients with Lower-Risk Myelodysplastic Syndromes (LR-MDS) Treated with Luspatercept: An Evaluation of US Clinical Practice Utilization and Treatment Patterns</u></a>
<b>431</b>	<a href="#"><u>Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial</u></a>
<b>459</b>	<a href="#"><u>Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study</u></a>
<b>460</b>	<a href="#"><u>Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial</u></a>
<b>462</b>	<a href="#"><u>Safety of Deferiprone in Patients with Myelodysplastic Syndromes: Results from the Deferiprone US Safety Registry and a Compassionate Use Program</u></a>
<b>853</b>	<a href="#"><u>Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)</u></a>
<b>854</b>	<a href="#"><u>Prolonged Survival in Bi-Allelic TP53-Mutated (TP53mut) MDS Subjects Treated with Oral Decitabine/Cedazuridine in the Ascertain Trial (ASTX727-02)</u></a>
<b>1774</b>	<a href="#"><u>Overall Survival and Progression-Free Survival of Patients Following Luspatercept Treatment in the MEDALIST Trial</u></a>

## Prognosis

<b>463</b>	<a href="#"><u>A Product of “Clash of Titans” or True Reflection of Disease Biology? Validation of 2022 WHO and ICC Classifications in a Large Dataset of Patients with Myelodysplastic Syndrome</u></a>
<b>464</b>	<a href="#"><u>Real-World Validation of Molecular International Prognostic Scoring System (IPSS-M) for Myelodysplastic Syndromes</u></a>
<b>465</b>	<a href="#"><u>Validation of the Molecular International Prognostic Scoring System (IPSS-M) Risk Stratification Model for Myelodysplastic Syndromes</u></a>
<b>466</b>	<a href="#"><u>Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools</u></a>
<b>559</b>	<a href="#"><u>Disease Characteristics and International Prognostic Scoring Systems (IPSS, IPSS-R, IPSS-M) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS) Participating in Two Randomized, Double-Blind, Placebo-Controlled Studies with Intravenous Sabatolimab Added to Hypomethylating Agents (HMA) (STIMULUS-MDS1 and MDS2)</u></a>
<b>857</b>	<a href="#"><u>A Clinically Practicable Approach to Predict TP53 Allelic Configurations in Myeloid Neoplasia</u></a>



Follow us on Twitter to keep up to date  
with the latest from the 64th ASH Annual  
Meeting & Exposition!

@MDS\_Hub  
#ASH22  
<https://mds-hub.com/>